The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine

Hayley C. Whitaker, Zsofia Kote-Jarai, Helen Ross-Adams, Anne Y. Warren, Johanna Burge, Anne George, Elizabeth Bancroft, Sameer Jhavar, Daniel Leongamornlert, Malgorzata Tymrakiewicz, Edward Saunders, Elizabeth Page, Anita Mitra, Gillian Mitchell, Geoffrey J. Lindeman, D. Gareth Evans, Ignacio Blanco, Catherine Mercer, Wendy S. Rubinstein, Virginia ClowesFiona Douglas, Shirley Hodgson, Lisa Walker, Alan Donaldson, Louise Izatt, Huw Dorkins, Alison Male, Kathy Tucker, Alan Stapleton, Jimmy Lam, Judy Kirk, Hans Lilja, Douglas Easton, IMPACT Study Steering Committee, IMPACT Study Collaborators, UK GPCS Collaborators, Colin Cooper, Rosalind Eeles, David E. Neal

Research output: Contribution to journalArticlepeer-review

72 Citations (Scopus)


Microseminoprotein-beta (MSMB) regulates apoptosis and using genome-wide association studies the rs10993994 single nucleotide polymorphism in the MSMB promoter has been linked to an increased risk of developing prostate cancer. The promoter location of the risk allele, and its ability to reduce promoter activity, suggested that the rs10993994 risk allele could result in lowered MSMB in benign tissue leading to increased prostate cancer risk.
Original languageEnglish
Article numbere13363
JournalPLoS One
Issue number10
Publication statusPublished - 13 Oct 2010


  • Alleles
  • Enzyme-Linked Immunosorbent Assay
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Immunohistochemistry
  • Male
  • Prostate-Specific Antigen
  • Prostatic Neoplasms
  • Prostatic Secretory Proteins
  • Tumor Markers, Biological

Cite this